Antibe Therapeutics (ATBPF) Stock Price, News & Analysis

Company Overview

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Key Stats

• Today's Range: $0.22 to $0.22
• 50-Day Range: $0.22 to $0.22
• 52-Week Range: $0.11 to $0.89
• Volume: N/A
• Average Volume: 27,352 shs
• Market Capitalization: $11.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ATBPF Stock Analysis - Frequently Asked Questions

How have ATBPF shares performed this year?

Antibe Therapeutics' stock was trading at $0.2156 at the start of the year. Since then, ATBPF stock has increased by 0.0% and is now trading at $0.2156.
View the best growth stocks for 2025 here.

How were Antibe Therapeutics' earnings last quarter?

Antibe Therapeutics Inc. (OTCMKTS:ATBPF) released its quarterly earnings data on Monday, November, 13th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.02.

How do I buy shares of Antibe Therapeutics?

Shares of ATBPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 11/13/2023
• Today: 4/30/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ATBPF
• CIK: N/A
• Web: www.antibethera.com
• Phone: (416) 922-3460
• Fax: N/A
• Employees: 11
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-14,730,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -56.48%
• Return on Assets: -29.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.06
• Quick Ratio: 10.06

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.58 per share
• Price / Book: 0.37

Miscellaneous

• Outstanding Shares: 52,981,000
• Free Float: 48,238,000
• Market Cap: $11.42 million
• Optionable: Not Optionable
• Beta: 0.51